VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

VolitionRx Limited (NYSE AMERICAN : VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026. Key Highlights: Sepsis & NETosis Validation: Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q ® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic shock patients. $7.3 million government-backed DETECSEPS program in France due to start recruitment in September 2026. Demonstrates Clinical Utility of Breakthrough Finger-Prick Detection of Nucleosomes : Expanding global market potential for sepsis testing using lateral flow, thereby potentially greatly expanding the addressable market and utility. European Lung Cancer Reimbursement: Plans formal conditional reimbursement submission in France by the end of 2026 to enable routine clinical use. First Half Revenue Growth : Reported $1.4M of revenue in the first half of 2026, representing a 112% increase year-over-year. Feline Lymphoma Manuscript Submission: Submitted for publication the clinical manuscript for the Nu.Q® Vet cancer test in cats; $5 million milestone payment anticipated subsequent to publication. Global Licensing Momentum: Confirms active discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies, including for technical evaluations. Newly Announced Collaboration: successfully transferred Volition Nu.Q ® NETs assay onto Sysmex Corporation's platform, in preparation for anticipated broader agreement. Sysmex Corporation is a multi-billion dollar market capitalization company listed on the Tokyo Stock Exchange. Capture-Seq™ Platform: Peer-reviewed paper published: validation cohort detected over 95% of Stage I and II cancers, Underscores a $23 billion annualized opportunity in cancer detection. Sepsis & NETosis Validation We were honored that Nu.Q ® NETs H3.1 featured in an editorial 1 in Critical Care Medicine, a prominent journal for Critical Care doctors around the world and were excited that the findings of another large-scale independent clinical study were peer-reviewed and published 2 in that journal. These findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market 3 . The inclusion of our Nu.Q® NETs assay in a real-world interventional evaluation of early detection of sepsis, in a government-backed (~$7.3 million) program in France remains on track to start in the third quarter of 2026. The DETECSEPS program provides an opportunity to receive individualized or personalized care, adjusted to the risk of deterioration and progression to sepsis. In the first half of 2026, we also reported two new, potentially large, clinical use cases for our Nu.Q ® NETs assay beyond sepsis. In conjunction with the Mayo Clinic 4 , we demonstrated Nu.Q ® NETs' potential clinical utility in aiding early risk identification which could inform targeted preventive strategies in acute trauma care 4 . We plan to further validate with Mayo the use of Nu.Q ® NETs in trauma patients. We have also demonstrated the potential use of Nu.Q ® NETs for patient management of a chronic disease, Hidradenitis Suppurativa 5 , which affects about 1% of the world's population 6 . NETosis-related diseases beyond sepsis provide an additional $1 billion Total Addressable Market on an annualized basis 3 . Breakthrough Finger-Prick Detection of Nucleosomes Excitingly for Nu.Q ® NETs we have also made excellent progress in the development and evaluation of our lateral flow prototype assay. This has the potential t...